Despite double-digit growth in revenue and profits, the stock price of Novo Nordisk A/S (NVO.US) has failed to meet market expectations.
In 2024, the global weight-loss drug market will still be hot, with Eli Lilly and Co raising its full-year revenue expectations and Novo Nordisk A/S lowering its full-year profit expectations.
Eli Lilly +5%, Named 'Top Pick' Following Q2 Beat Morgan Stanley Says
Barclays Remains a Buy on Eli Lilly & Co (LLY)
What Eli Lilly, Novo Nordisk Earnings Reveal About the Future of GLP-1 Sales
About 73% of the S&P 500 Names Beat on EPS During the Week - Earnings Scorecard
Why Are Hedge Funds Bullish on Eli Lilly and Company (LLY) Now?
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Laine Ford : that what up in the stock would